Altimmune to Participate in the Citizens Life Sciences Conference
Altimmune (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, has announced its upcoming participation in the Citizens Life Sciences Conference. The company's management team will engage in a fireside chat scheduled for Wednesday, May 7, 2025, at 9:30 a.m. EDT.
Interested parties can access the session through a webcast available in the Events section of the Altimmune website. This participation demonstrates the company's continued engagement with the investment community and commitment to transparency in communications.
Altimmune (Nasdaq: ALT), un'azienda biofarmaceutica in fase clinica avanzata, ha annunciato la sua prossima partecipazione alla Citizens Life Sciences Conference. Il team di gestione dell'azienda parteciperà a una chiacchierata informale prevista per mercoledì 7 maggio 2025 alle 9:30 EDT.
Gli interessati potranno seguire la sessione tramite un webcast disponibile nella sezione Eventi del sito web di Altimmune. Questa partecipazione dimostra l'impegno continuo dell'azienda verso la comunità degli investitori e la trasparenza nella comunicazione.
Altimmune (Nasdaq: ALT), una empresa biofarmacéutica en etapa clínica avanzada, ha anunciado su próxima participación en la Citizens Life Sciences Conference. El equipo directivo de la compañía participará en una charla informal programada para el miércoles 7 de mayo de 2025 a las 9:30 a.m. EDT.
Los interesados podrán acceder a la sesión a través de una transmisión en vivo disponible en la sección de Eventos del sitio web de Altimmune. Esta participación refleja el compromiso continuo de la compañía con la comunidad inversora y la transparencia en sus comunicaciones.
Altimmune (나스닥: ALT)는 후기 임상 단계의 바이오제약 회사로서, 다가오는 Citizens Life Sciences Conference에 참여할 예정임을 발표했습니다. 회사 경영진은 2025년 5월 7일 수요일 오전 9시 30분(동부 표준시)에 예정된 대화 세션에 참여할 예정입니다.
관심 있는 분들은 Altimmune 웹사이트의 이벤트 섹션에서 웹캐스트를 통해 세션에 접속할 수 있습니다. 이번 참여는 투자자 커뮤니티와의 지속적인 소통 및 투명성에 대한 회사의 의지를 보여줍니다.
Altimmune (Nasdaq : ALT), une entreprise biopharmaceutique en phase clinique avancée, a annoncé sa prochaine participation à la Citizens Life Sciences Conference. L'équipe de direction de la société participera à une discussion informelle prévue le mercredi 7 mai 2025 à 9h30 EDT.
Les personnes intéressées pourront accéder à la session via un webcast disponible dans la section Événements du site Web d'Altimmune. Cette participation témoigne de l'engagement continu de la société envers la communauté des investisseurs et de sa volonté de transparence dans ses communications.
Altimmune (Nasdaq: ALT), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, hat seine bevorstehende Teilnahme an der Citizens Life Sciences Conference angekündigt. Das Management-Team des Unternehmens wird an einem Gespräch am Kamin teilnehmen, das für Mittwoch, den 7. Mai 2025, um 9:30 Uhr EDT geplant ist.
Interessierte können die Sitzung über einen Webcast verfolgen, der im Veranstaltungsbereich der Altimmune-Website verfügbar ist. Diese Teilnahme zeigt das fortwährende Engagement des Unternehmens gegenüber der Investoren-Community und seine Verpflichtung zu transparenter Kommunikation.
- Late clinical-stage company status indicates advanced product development pipeline
- None.
GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Citizens Life Sciences Conference. Details are as follows:
| Conference: | Citizens Life Sciences Conference |
| Date/Time: | Wednesday, May 7, 2025, at 9:30 a.m. EDT |
The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH, alcohol use disorder as well as alcohol related liver disease. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Media Contact:
Jason Spark
Inizio Evoke, Biotech
Phone: 619-849-6005
Jason.spark@canalecomm.com
This press release was published by a CLEAR® Verified individual.
FAQ
When is Altimmune (ALT) presenting at the Citizens Life Sciences Conference 2025?
How can investors watch Altimmune's (ALT) Citizens Life Sciences Conference presentation?
What type of company is Altimmune (ALT) in 2025?
Where is the Citizens Life Sciences Conference 2025 with Altimmune (ALT) being held?
What format will Altimmune's (ALT) presentation take at the May 2025 Citizens conference?
